Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 3/20 | 0.44 |
| ▸ | PTGDR | Q13258 | 2/20 | 0.44 |
| ▸ | PDE4D | Q08499 | 4/20 | 0.35 |
| ▸ | PDE4A | P27815 | 3/20 | 0.35 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.35 |
| ▸ | PDE4C | Q08493 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.33 |
| ▸ | HTR2B | P41595 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19527578 | 0.81 | SLC6A2 (0.46) | PTGDR2PTGDRPDE4DPDE4APDE4B | |
| SCHEMBL27779806 | 0.80 | TAAR1 (0.39) | PTGDR2PTGDRPDE4DPDE4APDE4B | |
| SCHEMBL4311110 | 0.80 | PDE4D (0.33) | PTGDR2PTGDRPDE4DADRA1A | |
| SCHEMBL16961976 | 0.79 | PTGDR2 (0.44) | PTGDR2PTGDRPDE4DPDE4APDE4B | |
| SCHEMBL16961974 | 0.79 | PDE4D (0.35) | PTGDR2PTGDRPDE4DPDE4APDE4B | |
| SCHEMBL15716496 | 0.79 | HTR2B (0.34) | PTGDR2PTGDRPDE4DPDE4APDE4B | |
| SCHEMBL4306393 | 0.78 | PDE4A (0.39) | PTGDR2PTGDRPDE4DPDE4APDE4B | |
| SCHEMBL4311894 | 0.78 | PTGDR2 (0.36) | PTGDR2PTGDRPDE4DPDE4APDE4B | |
| SCHEMBL22804977 | 0.77 | PTGDR2 (0.47) | PTGDR2PTGDRPDE4DPDE4APDE4B | |
| SCHEMBL22804975 | 0.77 | PTGDR2 (0.47) | PTGDR2PTGDRPDE4DPDE4APDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010056194-A1 | 5H-PYRROLO [ 3, 4-B] PYRIDIN DERIVATIVES AND THEIR USE | ASTRAZENECA AB (SE) | 2010-05-20 | — | — | WO | disclosed |
| WO-2010056194-A1 | 5H-PYRROLO [ 3, 4-B] PYRIDIN DERIVATIVES AND THEIR USE | ASTRAZENECA AB (SE) | 2010-05-20 | — | — | WO | disclosed |
| US-20100125081-A1 | NEW COMPOUNDS 574 | ASTRAZENECA AB (SE) | 2010-05-20 | — | — | US | disclosed |
| US-20100125081-A1 | NEW COMPOUNDS 574 | ASTRAZENECA AB (SE) | 2010-05-20 | — | — | US | disclosed |
| US-20100125081-A1 | NEW COMPOUNDS 574 | ASTRAZENECA AB (SE) | 2010-05-20 | — | — | US | disclosed |
| CN-101641335-A | Amino-5-[substituted-4-(difluoromethoxy)phenyl]-5- phenylimidazolone compounds as ss-secretase inhibitors | WYETH CORP US | 2010-02-03 | — | — | CN | disclosed |
| EP-2137161-A1 | AMINO-5-[SUBSTITUTED-4-(DIFLUOROMETHOXY)PHENYL]-5- PHENYLIMIDAZOLONE COMPOUNDS AS ß-SECRETASE INHIBITORS | Wyeth a Corporation of the State of Delaware (US) | 2009-12-30 | — | — | EP | disclosed |
| US-20090042964-A1 | AMINO-5-[SUBSTITUTED-4-(DIFLUOROMETHOXY)PHENYL]-5-PHENYLIMIDAZOLONE COMPOUNDS AS BETA-SECRETASE INHIBITORS | WYETH (US) | 2009-02-12 | — | — | US | disclosed |
| WO-2008115552-A1 | AMINO-5-[SUBSTITUTED-4-(DIFLUOROMETHOXY)PHENYL]-5- PHENYLIMIDAZOLONE COMPOUNDS AS ß-SECRETASE INHIBITORS | WYETH (US) | 2008-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100125081-A1 | NEW COMPOUNDS 574 | PSEN1, PSEN2, BACE1 | PTGDR2 1645/4885PTGDR 1325/4885PDE4D 224/4885 |
| US-20090042964-A1 | AMINO-5-[SUBSTITUTED-4-(DIFLUOROMETHOXY)PHENYL]-5-PHENYLIMIDAZOLONE COMPOUNDS AS BETA-SECRETASE INHIBITORS | BACE1, BACE2, APP | PTGDR2 4586/4885PTGDR 4593/4885PDE4D 955/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.